Does LEUPROLIDE Cause Focal segmental glomerulosclerosis? 12 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Focal segmental glomerulosclerosis have been filed in association with LEUPROLIDE (Fensolvi). This represents 0.0% of all adverse event reports for LEUPROLIDE.
12
Reports of Focal segmental glomerulosclerosis with LEUPROLIDE
0.0%
of all LEUPROLIDE reports
0
Deaths
11
Hospitalizations
How Dangerous Is Focal segmental glomerulosclerosis From LEUPROLIDE?
Of the 12 reports, 11 (91.7%) required hospitalization, and 5 (41.7%) were considered life-threatening.
Is Focal segmental glomerulosclerosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LEUPROLIDE. However, 12 reports have been filed with the FAERS database.
What Other Side Effects Does LEUPROLIDE Cause?
Hot flush (9,146)
Death (8,772)
Intercepted product preparation error (8,621)
Syringe issue (7,847)
Device leakage (5,861)
Wrong technique in product usage process (5,062)
Fatigue (4,805)
Injection site pain (4,678)
Prostatic specific antigen increased (2,432)
Asthenia (2,176)
What Other Drugs Cause Focal segmental glomerulosclerosis?
TACROLIMUS (339)
MYCOPHENOLATE MOFETIL (181)
PREDNISONE (173)
CYCLOSPORINE (96)
METHYLPREDNISOLONE (81)
PREDNISOLONE (73)
RITUXIMAB (73)
BASILIXIMAB (67)
OMEPRAZOLE (60)
LANSOPRAZOLE (55)
Which LEUPROLIDE Alternatives Have Lower Focal segmental glomerulosclerosis Risk?
LEUPROLIDE vs LEVALBUTEROL
LEUPROLIDE vs LEVAMISOLE
LEUPROLIDE vs LEVAQUIN
LEUPROLIDE vs LEVEMIR
LEUPROLIDE vs LEVETIRACETAM